

Press Release – For immediate release

## **BIOLIDICS' STRATEGIC SHAREHOLDER, PROFESSOR XIE TIAN, VOLUNTARILY SUBJECTS HIS REMAINING STAKE IN BIOLIDICS TO A MORATORIUM**

- Previously, approximately 30.0% of Professor Xie Tian's entire stake in Biolidics was subjected to a moratorium of 12 months from the date of listing
- This voluntary undertaking applies to Professor Xie Tian's remaining 1,085,453 ordinary shares in Biolidics
- Reinforces Professor Xie Tian's commitment to expand Biolidics' presence and market opportunities in China

**Singapore, 15 January 2019 – Biolidics Limited ("Biolidics" or the "Company")**, a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce that its strategic shareholder and one of the Series C investors, Professor Xie Tian, has given an undertaking not to dispose of or sell any of his remaining 1,085,453 ordinary shares in Biolidics till 18 December 2019.

Professor Xie Tian is currently the Dean of the Department of Medical Oncology, Holistic Integrative Oncology Institute and Holistic Integrative Cancer Center of Traditional Chinese and Western Medicine in Hangzhou Normal University. He is a recipient of the Wu Jieping Medical Innovation Award in 2014, an award which honours top medical personnel in China, and the Prize for Scientific and Technological Innovation from the Ho Leung Ho Lee Foundation in 2016, an award that recognises scientific and technical personnel with outstanding contributions to the development of science and technology in China.

In China, Biolidics has entered into agreements with each of Hunan Agen Medicine Laboratory Technology Co., Ltd. and Holistic Integrative Pharmacy Institute, Hangzhou Normal University for the provision of its ClearCell® FX1 System and CTChip® FR1 biochips to them to facilitate the development of circulating tumor cells diagnostic services.

**Mr. Ivan Lew, Executive Director and CEO of Biolidics, said:** *"Professor Xie has strong credentials and he is highly regarded as a key opinion leader in China's oncology field. Hence, this is a significant endorsement of our disruptive patented technology that separates cancer cells from blood. There is great market potential in China with the liquid biopsy market expected to grow from US\$195.4 million in 2019 to US\$499.9 million in 2023\*."*

*"We look forward to work closely with Professor Xie and leverage on his extensive experience and network to advance our growth plans in China."*

\*Howe Sound Research, "LIQUID BIOPSY MARKETS" by Cancer Type by Diagnosis, Monitoring & Recurrence Testing. 2019 -2023 with Historical Data Including Screening Market Potential Size with Executive and Consultant Guides

**Professor Xie Tian added:** *“China has a rising cancer burden and Biolidics’ proprietary technology has strong potential to facilitate personalised medicine and targeted cancer treatments.*

*I strongly believe that Biolidics is uniquely positioned to forge productive partnerships in China, thereby creating new diagnostics solutions that benefit cancer patients and the general public.”*

**- END -**

### **About Biolidics Limited**

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

With ClearCell® FX1 Systems installed across Asia, Europe and North America, the ClearCell® FX1 System allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics’ quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and CFDA Class I registration (for the MGI EasyCell System).

For additional information, please visit [www.biolidics.com](http://www.biolidics.com).

***Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.***

### **Media Contacts:**



Mr. Alex TAN  
Mobile: +65 9451 5252  
Email: [alex.tan@8prasia.com](mailto:alex.tan@8prasia.com)

*This press release has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “SGX-ST”).*

*The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*